Phillips Anna Evans, Conwell Darwin L, Li Shuang, Saloman Jami L, Hart Phil A, Fogel Evan L, Vege Santhi Swaroop, Andersen Dana K, Fisher William E, Forsmark Christopher E, Pandol Stephen, Park Walter G, Topazian Mark D, Van Den Eeden Stephen K, Serrano Jose, Li Liang, Yadav Dhiraj
Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, USA.
Clin Transl Gastroenterol. 2025 May 1;16(5):e00807. doi: 10.14309/ctg.0000000000000807.
Opioids are used to treat pain in chronic pancreatitis (CP), but little is known about current use patterns. The aim of this study was to characterize the utilization of opioids and associations with clinical characteristics in adult patients with CP.
This cross-sectional analysis used baseline data from participants with definite CP enrolled in a cohort study in the United States (PROspective Evaluation of CP for EpidEmiologic and Translational StuDies). Data on demographics, pain medication use, healthcare utilization, disability, and pain patterns were systematically collected in case report forms while quality of life was assessed with patient-reported outcome instruments. Opioid use was classified according to strength (weak or strong) and frequency (scheduled or as-needed).
A total of 681 participants (n = 364, 53% male) were included: 299 (44%) were current opioid users (22% only weak opioids and 22% at least 1 strong opioid). Increasing frequency and severity of pain was associated with increase of weak, strong, as-needed, or scheduled opioids. Neuromodulators were used by ∼40% of participants; increasing use was associated with increasing frequency and severity of pain. On multivariate analysis, independent predictors associated with strength and frequency of current opioid use were pain patterns (odds ratios [ORs] 1.84-8.32 and ORs 1.92-8.52, respectively, P < 0.001) and prior celiac plexus block (OR 3.54, 95% confidence intervals 1.82-6.87 and OR 3.42, 95% confidence intervals 1.76-6.64, respectively). Participants using opioids had higher prevalence of disability, healthcare utilization, and poorer quality of life.
Opioid use in CP is common and associated with increased pain severity and constancy. These data provide foundational estimates for future trials that can elucidate the complex interactions between patient factors, pain, and interventions.
阿片类药物用于治疗慢性胰腺炎(CP)的疼痛,但目前对其使用模式知之甚少。本研究的目的是描述成年CP患者阿片类药物的使用情况及其与临床特征的关联。
这项横断面分析使用了在美国进行的一项队列研究(CP的前瞻性流行病学和转化研究评估)中确诊为CP的参与者的基线数据。通过病例报告表系统收集人口统计学、止痛药物使用、医疗保健利用、残疾和疼痛模式的数据,同时使用患者报告结局工具评估生活质量。阿片类药物的使用根据强度(弱或强)和频率(定期或按需)进行分类。
共纳入681名参与者(n = 364,53%为男性):299名(44%)为当前阿片类药物使用者(22%仅使用弱阿片类药物,22%至少使用一种强阿片类药物)。疼痛频率和严重程度的增加与弱阿片类药物、强阿片类药物、按需或定期使用阿片类药物的增加有关。约40%的参与者使用神经调节剂;使用频率增加与疼痛频率和严重程度增加有关。多变量分析显示,与当前阿片类药物使用强度和频率相关的独立预测因素是疼痛模式(优势比[OR]分别为1.84 - 8.32和OR 1.92 - 8.52,P < 0.001)和先前的腹腔神经丛阻滞(OR 3.54,95%置信区间1.82 - 6.87和OR 3.42,95%置信区间1.76 - 6.64)。使用阿片类药物的参与者残疾、医疗保健利用的患病率更高,生活质量更差。
CP患者中阿片类药物的使用很常见,且与疼痛严重程度和持续性增加有关。这些数据为未来的试验提供了基础估计,这些试验可以阐明患者因素、疼痛和干预措施之间的复杂相互作用。